It was interesting to read in the Australian article the reason why SPL went to Ansell. It's a shame it puts the product development timetable back because the cashflow would have been helpful. But, I feel confident that this company has good prospects and is going to be a good LT hold in my portfolio.
the australian - starpharma, page-4
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
